🇺🇸 FDA
Pipeline program

sotatercept, sotatercept

A011-12

Phase 3 small_molecule active

Quick answer

sotatercept, sotatercept for Pulmonary Arterial Hypertension (PAH) is a Phase 3 program (small_molecule) at Lacuna Pharma Pty Ltd with 1 ClinicalTrials.gov record(s).

Program details

Company
Lacuna Pharma Pty Ltd
Indication
Pulmonary Arterial Hypertension (PAH)
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials